WALTHAM, Mass., July 1 /PRNewswire-FirstCall/ -- Repligen Corporation
(Nasdaq: RGEN) announced today that Dr. Alfred L. Goldberg, Ph.D. has been
elected to its Board of Directors. Dr. Goldberg is currently a Professor of
Cell Biology at Harvard Medical School. He is a renowned scientist noted in
particular for elucidating the structure and function of the proteasome
which established the mechanism by which most proteins are destroyed in
cells. In addition, he has made major contributions to our understanding of
the importance of protein degradation in cell regulation, muscle atrophy,
immune surveillance, and protection against misfolded, toxic proteins. Dr.
Goldberg's research has led to the development of several drugs, including
Millennium Pharmaceutical's Velcade(R) for multiple myeloma.
"We are extremely pleased to welcome such an accomplished scientist to
our Board of Directors," stated Walter C. Herlihy, President and Chief
Executive Officer of Repligen Corporation. "Fred's expertise and
relationships within the scientific community and industry will be an
invaluable asset to the Company as we develop and expand our product
pipeline."
Dr. Goldberg has been associated with Harvard during his entire
academic career. He earned his A.B. in 1963, studied at Cambridge
University and Harvard Medical School, and earned his Ph.D. in 1968 from
Harvard University. He was appointed an Assistant Professor at Harvard
Medical School in 1969, immediately following one year as an Instructor.
Dr. Goldberg has been a Professor at Harvard Medical School since 1977. Dr.
Goldberg has served as a consultant to many biotechnology and
pharmaceutical companies and on numerous Scientific Advisory Boards
including the Michael J. Fox Foundation, The American Foundation for Aging
Research, The Gladstone Institute of Neurological Disease at The University
of California Medical School, and The Center for Neurodegenerative Disease
at Brigham and Women's Hospital to name a few. Dr. Goldberg has published
nearly 400 scientific articles and is an inventor on numerous patents.
About Repligen Corporation
Repligen Corporation is a biopharmaceutical company focused on the
development of novel therapeutics for diseases that affect the central
nervous system. In addition, we are the world's leading supplier of
recombinant Protein A, the sales of which partially fund the advancement of
our development pipeline while supporting our financial stability.
Repligen's corporate headquarters are located at 41 Seyon Street, Building
#1, Suite 100, Waltham, MA 02453. Additional information may be requested
from http://www.repligen.com.
This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. The forward-looking statements in this release do not
constitute guarantees of future performance. Investors are cautioned that
statements in this press release which are not strictly historical
statements, including, without limitation, statements regarding current or
future financial performance and position, management's strategy, plans and
objectives for future operations, plans and objectives for product
development, plans and objectives for present and future clinical trials
and results of such trials, plans and objectives for regulatory approval,
litigation, intellectual property, product development, manufacturing plans
and performance such as the anticipated growth in the monoclonal antibody
market and our other target markets and projected growth in product sales,
constitute forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated, including, without
limitation, risks associated with: the success of current and future
collaborative relationships, the market acceptance of our products, our
ability to compete with larger, better financed pharmaceutical and
biotechnology companies, new approaches to the treatment of our targeted
diseases, our expectation of incurring continued losses, our uncertainty of
product revenues and profits, our ability to generate future revenues, our
ability to raise additional capital to continue our drug development
programs, the success of our clinical trials, our ability to develop and
commercialize products, our ability to obtain required regulatory
approvals, our compliance with all Food and Drug Administration
regulations, our ability to obtain, maintain and protect intellectual
property rights for our products, the risk of litigation regarding our
intellectual property rights, our limited sales and manufacturing
capabilities, our dependence on third-party manufacturers and value added
resellers, our ability to hire and retain skilled personnel, our volatile
stock price, and other risks detailed in Repligen's filings with the
Securities and Exchange Commission. Repligen assumes no obligation to
update any forward-looking information contained in this press release or
with respect to the announcements described herein.
SOURCE Repligen Corporation
 back to top
Related links:
http://www.repligen.com
CONTACT:
Walter C. Herlihy, Ph.D., President and Chief
Executive Officer, +1-781-419-1900, or Laura L. Whitehouse, Vice
President, Market Development, +1-781-419-1812, both of Repligen
Corporation
|
